Gilead Sciences to buy 49.9% stake in Tizona Therapeutics for $300m

This article was originally published here

Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an

The post Gilead Sciences to buy 49.9% stake in Tizona Therapeutics for $300m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply